Philip Abbosh Receives 2018 BCAN Young Investigator Award

The 2018 BCAN Young Investigator Award will fund Abbosh’s work in next-generation sequencing to monitor disease response in upper tract urothelial carcinoma. If successful, this work will enhance urologists’ ability to determine the grade and stage of a patient’s disease and help decide whether surgery can safely be avoided.
The 2018 BCAN Young Investigator Award will fund Abbosh’s work in next-generation sequencing to monitor disease response in upper tract urothelial carcinoma. If successful, this work will enhance urologists’ ability to determine the grade and stage of a patient’s disease and help decide whether surgery can safely be avoided.

PHILADELPHIA (August 9, 2018) – Phillip Abbosh, MD, PhD, an assistant professor at Fox Chase Cancer Center and a graduate of Fox Chase’s Society of Urologic Oncology Fellowship Program, is the recipient of the Bladder Cancer Advocacy Network’s 2018 BCAN Young Investigator Award.

BCAN gives the Young Investigator Award to research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. It provides $50,000 to support one year of research. “Advancing quality research in early career investigators like Dr. Abbosh has always been a top priority for BCAN. Funding their work exemplifies our efforts to make a difference in the lives of those diagnosed with bladder cancer,” stated Andrea  
Maddox-Smith, Chief Executive Officer of BCAN. Learn more here.

Abbosh is a urologic oncologist and translational laboratory researcher. His lab is focused on the utility of urinary DNA from tumors to potentially guide treatment decisions for surgical patients with bladder and/or upper tract cancers. He is developing improved methods of applying this urinary biomarker platform to monitor disease grade, stage, and treatment response.

The 2018 BCAN Young Investigator Award will fund Abbosh’s work in next-generation sequencing to monitor disease response in upper tract urothelial carcinoma. If successful, this work will enhance urologists’ ability to determine the grade and stage of a patient’s disease and help decide whether surgery can safely be avoided.

Earlier this year Abbosh won Best Poster for his presentation of urinary DNA sequencing biomarkers research during the annual meeting of the American Urological Society.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427